Skip to main content

Table 3 Dietary composition and exercise volume during intervention period and post- ingestion period

From: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial

  Intervention period Post-ingestion period
Item Group n Week-0 Week-4 Week-8 Week-12 Week-16
Energy (kcal/3d) Placebo 14 6075 ± 1336 5925 ± 934 5648 ± 1108** 5623 ± 872 5488 ± 924*
GH 15 5599 ± 1387 5748 ± 1500 5383 ± 1250 5322 ± 1259 5328 ± 1013
GH + Caf 25 15 5606 ± 1270 5512 ± 1031 5252 ± 1340 4981 ± 1291 5155 ± 1395
GH + Caf 50 15 5240 ± 1463 5774 ± 1666 5425 ± 1538 5302 ± 1723 5272 ± 1635
GH + Caf 75 15 5727 ± 929 5268 ± 1369 5546 ± 1302 5119 ± 1538 5401 ± 1618
Exercise volume (step/3d) Placebo 14 21661 ± 12162 22372 ± 9366 27058 ± 11735 25258 ± 10247 23994 ± 10039
GH 15 17118 ± 7809 22161 ± 15033 19231 ± 8677 22738 ± 11305* 20298 ± 8622
GH + Caf 25 15 19929 ± 8679 22946 ± 14412 22350 ± 16172 19656 ± 16855 22996 ± 14817
GH + Caf 50 15 23513 ± 13156 21881 ± 12157 22491 ± 9911 23005 ± 12524 24650 ± 12288
GH + Caf 75 15 18843 ± 7455 19828 ± 6532 24016 ± 8703 24036 ± 9488 23972 ± 8216
  1. GH glucosyl hesperidin 500 mg, Caf 25, 50, 75 caffeine 25 mg, 50 mg, 75 mg
  2. Data are the mean ± SD recorded 3 days before each check-up
  3. *p < 0.05, **p < 0.01 vs. baseline (week-0), (paired t-test)